Episodios

  • MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

    MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
    Apr 16 2026
    MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) by Foundation Fighting Blindness
    Más Menos
    3 m
  • Opus Genetics Secures $155 Million Financing to Accelerate Gene Therapy Pipeline

    Opus Genetics Secures $155 Million Financing to Accelerate Gene Therapy Pipeline
    Apr 8 2026
    Strategic funding extends cash runway through 2029 and advances multiple inherited retinal disease programs
    Más Menos
    3 m
  • VeonGen Reports Promising Clinical Progress for Stargardt Disease Gene Therapy

    VeonGen Reports Promising Clinical Progress for Stargardt Disease Gene Therapy
    Mar 26 2026
    VG801 shows sustained vision improvements through 12 months with favorable safety profile
    Más Menos
    3 m
  • Sumitomo Pharma Receives FDA Orphan Drug Designation for Retinitis Pigmentosa Treatment

    Sumitomo Pharma Receives FDA Orphan Drug Designation for Retinitis Pigmentosa Treatment
    Mar 24 2026
    Potential cell therapy, DSP-3077, gains special regulatory status to support development for inherited retinal disease.
    Más Menos
    2 m
  • Octant Bio Begins Clinical Testing Oral Treatment for Rhodopsin-Related Retinitis Pigmentosa

    Octant Bio Begins Clinical Testing Oral Treatment for Rhodopsin-Related Retinitis Pigmentosa
    Mar 11 2026
    First-of-its-kind small molecule therapy targets protein misfolding at the root of RHO-adRP
    Más Menos
    2 m
  • Opus Genetics Reports Promising Early Results from BEST1 Gene Therapy Trial

    Opus Genetics Reports Promising Early Results from BEST1 Gene Therapy Trial
    Mar 2 2026
    First patient shows vision improvements with a good safety profile.
    Más Menos
    3 m
  • Eye on the Cure Podcast | Episode 100: BEST OF

    Eye on the Cure Podcast | Episode 100: BEST OF
    Feb 27 2026
    To celebrate episode 100 of Eye on the Cure, host Ben Shaberman features highlights from conversations with some of his previous guests including: Dr. Dean Bok from UCLA, Dr. Michel Michaelides from Moorfields Eye Hospital, actor Ben Mehl, triathlete Michael Stone, and jazz keyboardist Matthew Whitaker. This "Best Of" episode is Ben's final for Eye on the Cure, but the podcast will continue on with a new host. Stay tuned!
    Más Menos
    36 m
  • SparingVision Completes Dosing in Gene-Agnostic Therapy Trial for Retinitis Pigmentosa (RP)

    SparingVision Completes Dosing in Gene-Agnostic Therapy Trial for Retinitis Pigmentosa (RP)
    Feb 11 2026
    Novel neuroprotective approach could benefit RP patients regardless of genetic mutation
    Más Menos
    3 m